

# Courtney Thorne

Partner



cthorne@cooley.com

+1 617 937 2318

Boston

Capital Markets  
Public Companies  
Life Sciences

Courtney's practice focuses on the representation of public companies and investment banks in the life sciences industry – with an emphasis on capital raising, public company counseling, foreign private issuer matters and securities law compliance. In addition to a robust US practice, she also has substantial experience advising non-US companies, known as foreign private issuers (FPIs), seeking to access the US capital markets or list on a US securities exchange. Over the past six years, Courtney has advised 45+ IPOs and follow-on offerings, with an aggregate value of more than \$4.2 billion.

Courtney regularly acts as primary outside counsel for a number of publicly traded clients, advising companies and their boards of directors with respect to SEC periodic reporting and disclosure obligations, strategic corporate decisions, annual meeting and proxy-related issues, beneficial ownership reporting, securities exchange listing standards, corporate governance, and Sarbanes-Oxley Act compliance, as well as other general corporate and securities matters.

Courtney also represents domestic and foreign issuers, investment banks and financial institutions in connection with initial and follow-on public offerings, shelf registrations and shelf takedown offerings, Regulation S offerings, registered direct offerings, at-the-market (ATM) offerings, private investments in public equity (PIPEs), and private placements of equity and debt securities by life sciences companies.

Since 2015, Courtney has been recognized as a Massachusetts Super Lawyers' Rising Star in the fields of Securities & Corporate Finance and Business & Corporate.

Before joining Cooley, Courtney was an associate in the Boston office of an international law firm. While in law school, she worked as an intern – and later as a consultant – for the in-house legal department of Cubist Pharmaceuticals, a publicly traded biopharmaceutical company based in Lexington, Massachusetts, which later sold to Merck.

## Courtney's representative company transactions

- **Exscientia** in its \$510.4 million IPO, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation
- **Finch Therapeutics** in its \$127.5 million IPO
- **Immunocore** in its \$312.1 million aggregate financing, consisting of a \$297.1 million IPO of ordinary shares in the form of American Depositary Shares (ADSs), full exercise of the option to purchase additional ADSs and a \$15 million concurrent private placement to the Bill & Melinda Gates Foundation
- **Repare Therapeutics** in its \$253 million IPO, \$88 million follow-on offering, public company representation and securities law compliance

- **Oncorus** in its \$87 million IPO, \$57 million follow-on offering and public company representation
- **Exicure** in its \$50 million ATM facility, \$25 million debt facility and public company representation
- **X4 Pharmaceuticals** in its \$50 million equity facility, \$50 million ATM facility, \$65 million follow-on offering and public company representation
- **Autolus Therapeutics** in its \$172.5 million IPO of ordinary shares in the form of ADSs, \$100.8 million follow-on offering, \$80 million follow-on offering, \$115 million follow-on offering, \$100 million ATM facility, US public company representation and securities law compliance
- **ERYTECH Pharma** in its \$143.7 million initial public offering of ordinary shares, including in the form of ADSs, its 70.5 million euro, 25.5 million euro and 10 million euro private placements of ordinary shares to US and European investors, \$30 million ATM facility, \$30 million registered direct offering, US public company representation and securities law compliance
- **Nightstar Therapeutics** in its \$86 million IPO of ordinary shares in the form of ADSs, US public company representation and securities law compliance
- **Taiwan Liposome Company** in its \$22.7 million IPO of ADSs
- **ZIOPHARM Oncology** in its \$50 million underwritten registered direct offering, \$50 million PIPE, \$90.4 million follow-on offering, strategic collaborations and public company representation
- **DBV Technologies** in its \$281.5 million follow-on offering of ordinary shares in the form of ADSs
- Numerous Regulation S and Rule 144A offerings of US and non-US companies raising capital

#### **Courtney's representative investment bank and underwriter clients**

Courtney regularly represents a number of leading investment banks – including BMO Capital Markets, Citigroup, Cowen, Evercore ISI, Goldman Sachs, Guggenheim, Jefferies, J.P. Morgan, Stifel Nicolaus, SVB Leerink, Wedbush and William Blair – on a wide number of transactions, including the following most recent transactions:

- **Merus** in its:
  - \$173 million follow-on offering
  - \$120 million follow-on offering
  - \$75 million ATM facility
  - \$61.4 million IPO
- **Nanobiotix** in its \$113.3 million IPO
- **Deciphera Pharmaceuticals** in its \$200 million ATM facility
- **Translate Bio** in its \$275.1 million follow-on offering
- **NuCana** in its:
  - \$80.5 million follow-on offering
  - \$100 million ATM facility
  - \$114 million IPO

#### **Courtney's representative mergers & acquisitions/reverse mergers**

- **Proteostasis Therapeutics** in its acquisition by Yumanity Therapeutics
- **Avedro** in its \$70 million IPO and acquisition by Glaukos
- **Biodel** in its acquisition by Albireo Pharma

## Education

Suffolk University Law School  
JD, 2010

George Washington University  
MPA, 2007

George Washington University  
BA, 2005

## Admissions & Credentials

Massachusetts

New York

## Rankings & Accolades

Massachusetts Super Lawyers: Rising Star in Business/Corporate Law and Securities & Corporate Finance  
(2015 – 2023)

#1 Firm for European FPI US IPOs since 2016

## Memberships & Affiliations

Boston Bar Association

Healthcare Businesswomen's Association